Production (Stage)
scPharmaceuticals Inc.
SCPH
$3.55
-$0.03-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 138.10% | 167.28% | 303.87% | 549.77% | 754.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 138.10% | 167.28% | 303.87% | 549.77% | 754.68% |
| Cost of Revenue | 161.41% | 198.11% | 349.90% | 623.36% | 724.96% |
| Gross Profit | 128.90% | 155.27% | 286.68% | 524.03% | 767.01% |
| SG&A Expenses | 36.20% | 45.49% | 63.68% | 79.26% | 109.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.51% | 46.56% | 64.46% | 74.09% | 81.80% |
| Operating Income | -11.69% | -16.93% | -28.30% | -34.79% | -47.50% |
| Income Before Tax | -57.31% | -55.35% | -59.45% | -35.44% | -43.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.31% | -55.35% | -59.45% | -35.44% | -43.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.31% | -55.35% | -59.45% | -35.44% | -43.14% |
| EBIT | -11.69% | -16.93% | -28.30% | -34.79% | -47.50% |
| EBITDA | -11.71% | -16.95% | -28.33% | -34.83% | -47.57% |
| EPS Basic | -28.59% | -34.13% | -40.33% | -17.36% | -12.89% |
| Normalized Basic EPS | -26.07% | -30.92% | -46.40% | -21.49% | -17.04% |
| EPS Diluted | -28.59% | -34.13% | -40.33% | -17.36% | -12.89% |
| Normalized Diluted EPS | -26.07% | -30.92% | -46.40% | -21.49% | -17.04% |
| Average Basic Shares Outstanding | 24.16% | 15.53% | 11.45% | 15.05% | 25.32% |
| Average Diluted Shares Outstanding | 24.16% | 15.53% | 11.45% | 15.05% | 25.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |